Unchartered Territory: When Should Patients Stop Immunotherapy?
For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?
Melanoma Treatment Advances – 2018 in Review
2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.
MRA Advisor & Grantee Dr. Allison Awarded Nobel Prize for Transforming Cancer Care
MRA Scientific Advisory Panel Member & Grantee Dr. Allison Awarded Nobel Prize for his pioneering research to harness the power of the immune system to attack cancer. His work in immunotherapy, which began in the 1990’s, was audacious at the time. It helped to mainstream an entirely new class of tools in the arsenal against cancer; joining the likes of chemotherapy, radiation, and surgery.
Dr. Marc Hurlbert Joins MRA as Chief Science Officer
Dr. Marc Hurlbert has built his career advancing medical research in support of patients. Now, as of this month, he will translate his skills, relationships, and enthusiasm to achieving our mission of ending death and suffering due to melanoma as MRA’s Chief Science Officer.
Improving the Lives of Melanoma Survivors
Melanoma survivors are at a 9-fold increased risk of developing another melanoma. Unfortunately, 20% of survivors reported a sunburn in the past year and 10% intentionally went outside for a tan – both strong predictors of inappropriate sun exposure.
Using Zebrafish to Shed New Light on Melanoma
Dr. Liz Patton, a MRA-funded cancer researcher at the Medical Research Council Human Genetics Unit at the University of Edinburgh, is fascinated by learning how things work. Patton has focused her research on better understanding how melanocytes – the cells in our skin that provide us our coloring – develop, divide, migrate, and in some unfortunate circumstances, proliferate uncontrollably turning into melanoma. Her work is providing critical insight into the origin of melanoma and what spurs melanoma to spread throughout the body.
Maintaining the Pace of Melanoma Innovation in the Era of an Evolving Standard of Care
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 August 2018 In Science, Treatment
There is no doubt that treatments for metastatic melanoma have changed dramatically in the decade since MRA’s founding in 2007. How do we keep up the momentum?
Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC
When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.